Renal disorder – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Thu, 18 Jun 2026 04:08:05 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Renal disorder – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases https://clinicaltrials.eu/trial/bi-764198-in-adults-and-adolescents-with-proteinuric-kidney-diseases/ Tue, 02 Jun 2026 04:17:47 +0000 https://clinicaltrials.eu/trial/bi-764198-in-adults-and-adolescents-with-proteinuric-kidney-diseases/ This clinical trial is studying proteinuric kidney diseases, which are kidney disorders that cause too much protein to leak into the urine. The study is testing BI 764198, an oral tablet, against a placebo matching BI 764198. The purpose of the study is to see whether BI 764198 is safe and helpful for adults and adolescents with four related kidney conditions: focal segmental glomerulosclerosis (a kidney disease that scars parts of the kidney filter), treatment-resistant primary minimal change disease (a kidney disease that does not improve with usual treatment), Alport syndrome (an inherited kidney disease that can also affect hearing and vision), and treatment-resistant primary membranous nephropathy (a kidney disease caused by damage to the kidney filters). Some participants may already be receiving other kidney medicines such as SGLT2i/CNI, which are drugs often used to protect kidney function and reduce protein loss in the urine.

The study is planned in two groups, and neither the participants nor the study team will know which treatment is given. After starting treatment, the medicine is taken for a period of time and then the study looks at changes in urine protein and kidney function over about 20 weeks. The study is designed to compare BI 764198 with placebo across the different kidney disease groups.

]]> A study to evaluate the safety of ADX-038 in patients with complement-mediated kidney disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-adx-038-in-patients-with-complement-mediated-kidney-disease/ Wed, 29 Apr 2026 15:09:15 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-of-adx-038-in-patients-with-complement-mediated-kidney-disease/ This study focuses on individuals living with Complement-Mediated Kidney Disease, a rare condition where the immune system’s proteins, known as the complement system, mistakenly attack the kidneys. The investigation aims to evaluate the safety and tolerability of the drug ADX-038. This medication is administered via a subcutaneous injection, which is a method of delivering medicine through a small needle just under the skin.

During the course of the study, participants will receive the study drug to monitor how the body reacts to it. Researchers will observe the effects of ADX-038 over time, specifically looking for any side effects or changes in the amount of protein released in the urine, which is often measured through a UPCR (urine protein-to-creatinine ratio) test. This test helps in understanding how well the kidneys are functioning.

]]> Study on Spinal Morphine, Intravenous Lidocaine, and Bupivacaine for Patients Undergoing Robot-Assisted Surgery for Kidney or Ureter Conditions https://clinicaltrials.eu/trial/study-on-spinal-morphine-intravenous-lidocaine-and-bupivacaine-for-patients-undergoing-robot-assisted-surgery-for-kidney-or-ureter-conditions/ Wed, 29 Apr 2026 14:26:24 +0000 https://clinicaltrials.eu/trial/study-on-spinal-morphine-intravenous-lidocaine-and-bupivacaine-for-patients-undergoing-robot-assisted-surgery-for-kidney-or-ureter-conditions/ This clinical trial is focused on improving recovery after surgery for patients undergoing robot-assisted upper urinary tract surgery, which is a type of surgery involving the kidneys or ureters. The study is particularly interested in conditions such as renal cancer, ureter cancer, benign kidney tumors, kidney stones, and kidney reflux. The trial will explore the effects of different pain management strategies during and after surgery.

Participants in the study will receive one of the following treatments: spinal morphine, which is derived from the opium poppy and administered directly into the spinal fluid, or intravenous lidocaine, a common local anesthetic given through a vein. Additionally, some patients will receive a combination of bupivacaine, another local anesthetic, and adrenaline, which helps prolong the effects of the anesthetic. The purpose of the study is to determine if these treatments can enhance recovery after surgery, as measured by a patient-centered outcome scale called “Quality of Recovery 15.”

The study will involve a random assignment of treatments to participants, and it will be conducted without the participants knowing which treatment they are receiving. The trial will monitor recovery progress, including pain levels and overall well-being, at various points after surgery. The goal is to find the most effective pain management strategy to improve the recovery experience for patients undergoing this type of surgery.

]]>